Analysts’ Weekly Ratings Changes for Cytosorbents (CTSO)

A number of firms have modified their ratings and price targets on shares of Cytosorbents (NASDAQ: CTSO) recently:

• 1/13/2025 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/13/2025 – Cytosorbents had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
• 1/5/2025 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 1/3/2025 – Cytosorbents had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
• 12/28/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/20/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/12/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 12/4/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/26/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 11/18/2024 – Cytosorbents is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.

Cytosorbents Trading Up 12.0 %

NASDAQ CTSO traded up $0.11 during trading on Monday, hitting $1.05. The stock had a trading volume of 453,408 shares, compared to its average volume of 1,251,073. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The stock has a market capitalization of $57.41 million, a price-to-earnings ratio of -2.92 and a beta of 0.58. Cytosorbents Co. has a one year low of $0.70 and a one year high of $1.59. The stock has a 50 day simple moving average of $0.92 and a 200 day simple moving average of $1.03.

Hedge Funds Weigh In On Cytosorbents

Institutional investors have recently bought and sold shares of the business. Atomi Financial Group Inc. purchased a new position in Cytosorbents in the third quarter worth $51,000. Geode Capital Management LLC grew its holdings in Cytosorbents by 7.5% in the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC grew its holdings in Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 67,181 shares during the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.